{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:37:56Z","timestamp":1788975476054,"version":"build-2803163510"},"reference-count":26,"publisher":"Bioscientifica","issue":"3","license":[{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["etj.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,18]]},"abstract":"<jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>\n                      Two-thirds of metastatic differentiated thyroid cancer (DTC) patients have radioiodine (RAI)-resistant disease, resulting in poor prognosis and high mortality. For rare\n                      <jats:italic>NTRK<\/jats:italic>\n                      and\n                      <jats:italic>RET<\/jats:italic>\n                      fusion-positive metastatic, RAI-resistant thyroid cancers, variable success of re-induction of RAI avidity during treatment with\n                      <jats:italic>NTRK<\/jats:italic>\n                      or\n                      <jats:italic>RET<\/jats:italic>\n                      inhibitors has been reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation and results<\/jats:title>\n                    <jats:p>\n                      We report two cases with RAI-resistant lung metastases treated with larotrectinib: an 83-year-old male presenting with an\n                      <jats:italic>ETV6::NTRK3<\/jats:italic>\n                      fusion-positive tumor with the\n                      <jats:italic>TERT<\/jats:italic>\n                      promoter mutation c.-124C&gt;T, and a 31-year-old female presenting with a\n                      <jats:italic>TPR::NTRK1<\/jats:italic>\n                      fusion-positive tumor (and negative for\n                      <jats:italic>TERT<\/jats:italic>\n                      promoter mutation). Post larotrectinib treatment, diagnostic I-123 whole body scan revealed unsuccessful RAI-uptake re-induction in the\n                      <jats:italic>TERT<\/jats:italic>\n                      -positive tumor, with a thyroid differentiation score (TDS) of \u22120.287. In contrast, the\n                      <jats:italic>TERT<\/jats:italic>\n                      -negative tumor exhibited successful I-131 reuptake with a TDS of \u22120.060.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      As observed for RAI-resistance associated with concurrent\n                      <jats:italic>TERT<\/jats:italic>\n                      and BRAF mutations, the co-occurrence of\n                      <jats:italic>TERT<\/jats:italic>\n                      mutations and\n                      <jats:italic>NTRK<\/jats:italic>\n                      fusions may also contribute to re-sensitization failure.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/etj-23-0227","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T13:12:23Z","timestamp":1713445943000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-16","source":"Crossref","is-referenced-by-count":14,"title":["Predictors of radioiodine (RAI)-avidity restoration for NTRK fusion-positive RAI-resistant metastatic thyroid cancers"],"prefix":"10.1530","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1023-6039","authenticated-orcid":true,"given":"Abdul Rehman","family":"Syed","sequence":"first","affiliation":[{"name":"University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aakash","family":"Gorana","sequence":"additional","affiliation":[{"name":"Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Nohr","sequence":"additional","affiliation":[{"name":"Alberta Precision Laboratories, Molecular Pathology Program, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli-Kat","family":"Yuan","sequence":"additional","affiliation":[{"name":"Precision Oncology Hub Laboratory, Tom Baker Cancer Centre, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parthiv","family":"Amin MASc","sequence":"additional","affiliation":[{"name":"Department of Radiology, Cumming School of Medicine, University of Calgary, Calgary Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Ghaznavi","sequence":"additional","affiliation":[{"name":"Arnie Charbonneau Cancer Institute, Department of Medicine, Section of Endocrinology, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie","family":"Lamb","sequence":"additional","affiliation":[{"name":"Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"McIntyre","sequence":"additional","affiliation":[{"name":"Precision Oncology Hub Laboratory, Tom Baker Cancer Centre, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4732-2934","authenticated-orcid":true,"given":"Markus","family":"Eszlinger","sequence":"additional","affiliation":[{"name":"Department of Oncology, Cumming School of Medicine, and Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1470-268X","authenticated-orcid":true,"given":"Ralf","family":"Paschke","sequence":"additional","affiliation":[{"name":"Departments of Medicine, Section of Endocrinology, Oncology, Pathology and Laboratory Medicine, Biochemistry and Molecular Biology and Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","series-title":"Thyroid","first-page":"1","article-title":"2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","unstructured":"Haugen BRAlexander EKBible KCDoherty GMMandel SJNikiforov YEPacini FRandolph GWSawka AMSchlumberger M, et al.2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid2016261\u2013133. (https:\/\/doi.org\/10.1089\/thy.2015.0020)"},{"key":"bib2","series-title":"Thyroid","first-page":"1771","article-title":"RET, NTRK, ALK, BRAF, and MET fusions in a large cohort of pediatric papillary thyroid carcinomas","volume":"30","author":"Pekova","year":"2020","unstructured":"Pekova BSykorova VDvorakova SVaclavikova EMoravcova JKatra RAstl JVlcek PKodetova DVcelak J, et al.RET, NTRK, ALK, BRAF, and MET fusions in a large cohort of pediatric papillary thyroid carcinomas. Thyroid2020301771\u20131780. (https:\/\/doi.org\/10.1089\/thy.2019.0802)"},{"key":"bib3","series-title":"New England Journal of Medicine","first-page":"1054","article-title":"Biologic and clinical perspectives on thyroid cancer","volume":"375","author":"Fagin","year":"2016","unstructured":"Fagin JA & Wells SA. Biologic and clinical perspectives on thyroid cancer. New England Journal of Medicine20163751054\u20131067. (https:\/\/doi.org\/10.1056\/NEJMra1501993)"},{"key":"bib4","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"2892","article-title":"Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy","volume":"91","author":"Durante","year":"2006","unstructured":"Durante CHaddy NBaudin ELeboulleux SHartl DTravagli JPCaillou BRicard MLumbroso JDDe Vathaire F, et al.Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. Journal of Clinical Endocrinology and Metabolism2006912892\u20132899. (https:\/\/doi.org\/10.1210\/jc.2005-2838)"},{"key":"bib5","series-title":"Cell","first-page":"676","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","author":"Agarwal","year":"2014","unstructured":"Agarwal NAkbani RAksoy BAAlly AArachchi H & Asa SL. Integrated genomic characterization of papillary thyroid carcinoma. Cell2014159676\u2013690. (https:\/\/doi.org\/10.1016\/j.cell.2014.09.050)"},{"key":"bib6","series-title":"New England Journal of Medicine","first-page":"623","article-title":"Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer","volume":"368","author":"Ho","year":"2013","unstructured":"Ho ALGrewal RKLeboeuf RSherman EJPfister DGDeandreis DPentlow KSZanzonico PBHaque SGavane S, et al.Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. New England Journal of Medicine2013368623\u2013632. (https:\/\/doi.org\/10.1056\/NEJMoa1209288)"},{"key":"bib7","series-title":"Clinical Cancer Research","first-page":"1028","article-title":"Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib","volume":"21","author":"Rothenberg","year":"2015","unstructured":"Rothenberg SMMcFadden DGPalmer ELDaniels GH & Wirth LJ. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib. Clinical Cancer Research2015211028\u20131035. (https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2915)"},{"key":"bib8","series-title":"New England Journal of Medicine","first-page":"1686","article-title":"Larotrectinib-enhanced radioactive iodine uptake in advanced thyroid cancer","volume":"383","author":"Groussin","year":"2020","unstructured":"Groussin LClerc J & Huillard O. Larotrectinib-enhanced radioactive iodine uptake in advanced thyroid cancer. New England Journal of Medicine20203831686\u20131687. (https:\/\/doi.org\/10.1056\/NEJMc2023094)"},{"key":"bib9","series-title":"Thyroid","first-page":"1603","article-title":"Letter to the editor: selpercatinib-enhanced radioiodine uptake in RET-rearranged thyroid cancer","volume":"31","author":"Groussin","year":"2021","unstructured":"Groussin LBessiene LArrondeau JGarinet SCochand-Priollet BLupo AZerbit JClerc J & Huillard O. Letter to the editor: selpercatinib-enhanced radioiodine uptake in RET-rearranged thyroid cancer. Thyroid2021311603\u20131604. (https:\/\/doi.org\/10.1089\/thy.2021.0144)"},{"key":"bib10","series-title":"Journal of Clinical Investigation","first-page":"e144847","article-title":"NTRK and RET fusion\u2013directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake","volume":"131","author":"Lee","year":"2021","unstructured":"Lee YALee HIm SWSong YSOh DYKang HJWon JKJung KCKwon DChung EJ, et al.NTRK and RET fusion\u2013directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake. Journal of Clinical Investigation2021131e144847. (https:\/\/doi.org\/10.1172\/JCI144847)"},{"key":"bib11","series-title":"Thyroid","first-page":"594","article-title":"Redifferentiating effect of larotrectinib in NTRK-rearranged advanced radioactive-iodine refractory thyroid cancer","volume":"32","author":"Groussin","year":"2022","unstructured":"Groussin LTheodon HBessiene LBricaire LBonnet-Serrano FCochand-Priollet BLeroy KGarinet SPasmant EZerbit J, et al.Redifferentiating effect of larotrectinib in NTRK-rearranged advanced radioactive-iodine refractory thyroid cancer. Thyroid202232594\u2013598. (https:\/\/doi.org\/10.1089\/thy.2021.0524)"},{"key":"bib12","series-title":"Canadian Journal of Health Technologies","article-title":"Radioiodine resensitization for radioiodine-refractory metastatic differentiated thyroid cancer","volume":"2","author":"Goring","year":"2022","unstructured":"Goring S & Mahood Q. Radioiodine resensitization for radioiodine-refractory metastatic differentiated thyroid cancer. Canadian Journal of Health Technologies20222. (https:\/\/doi.org\/10.51731\/cjht.2022.309)"},{"key":"bib13","series-title":"Thyroid","first-page":"1124","article-title":"MERAIODE: A Phase II redifferentiation trial with trametinib and 131I in metastatic radioactive iodine refractory RAS mutated differentiated thyroid cancer","volume":"33","author":"Leboulleux","year":"2023","unstructured":"Leboulleux SBenisvy DTaieb DAttard MBournaud CTerroir-Cassou-Mounat MLacroix LAnizan NSchiazza AGarcia ME, et al.MERAIODE: A Phase II redifferentiation trial with trametinib and 131I in metastatic radioactive iodine refractory RAS mutated differentiated thyroid cancer. Thyroid2023331124\u20131129. (https:\/\/doi.org\/10.1089\/thy.2023.0240)"},{"key":"bib14","series-title":"Clinical Cancer Research","first-page":"2401","article-title":"A Phase II redifferentiation trial with Dabrafenib-Trametinib and 131I in metastatic radioactive iodine refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer","volume":"29","author":"Leboulleux","year":"2023","unstructured":"Leboulleux SDo Cao CZerdoud SAttard MBournaud CLacroix LBenisvy DTa\u00efeb DBardet STerroir-Cassou-Mounat M, et al.A Phase II redifferentiation trial with Dabrafenib-Trametinib and 131I in metastatic radioactive iodine refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer. Clinical Cancer Research2023292401\u20132409. (https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0046)"},{"key":"bib15","series-title":"Cancer Discovery","first-page":"1158","article-title":"SWI\/SNF complex mutations promote thyroid tumor progression and insensitivity to redifferentiation therapies","volume":"11","author":"Saqcena","year":"2021","unstructured":"Saqcena MLeandro-Garcia LJMaag JLVTchekmedyian VKrishnamoorthy GPTamarapu PPTiedje VReuter VKnauf JAde Stanchina E, et al.SWI\/SNF complex mutations promote thyroid tumor progression and insensitivity to redifferentiation therapies. Cancer Discovery2021111158\u20131175. (https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0735)"},{"key":"bib16","series-title":"Journal of Nuclear Medicine","first-page":"177","article-title":"The genetic duet of BRAF V600E and TERT promoter mutations robustly predicts loss of radioiodine avidity in recurrent papillary thyroid cancer","volume":"61","author":"Liu","year":"2020","unstructured":"Liu JLiu RShen XZhu GLi B & Xing M. The genetic duet of BRAF V600E and TERT promoter mutations robustly predicts loss of radioiodine avidity in recurrent papillary thyroid cancer. Journal of Nuclear Medicine202061177\u2013182. (https:\/\/doi.org\/10.2967\/jnumed.119.227652)"},{"key":"bib17","series-title":"Thyroid","first-page":"751","article-title":"Updated American Joint Committee on Cancer\/Tumor-Node-Metastasis Staging System for differentiated and anaplastic thyroid cancer (eighth edition): what changed and why?","volume":"27","author":"Tuttle","year":"2017","unstructured":"Tuttle RMHaugen BPerrier ND. Updated American Joint Committee on Cancer\/Tumor-Node-Metastasis Staging System for differentiated and anaplastic thyroid cancer (eighth edition): what changed and why?Thyroid201727751\u2013756. (https:\/\/doi.org\/10.1089\/thy.2017.0102)"},{"key":"bib18","series-title":"European Thyroid Journal","first-page":"e210061","article-title":"Systematic population-based identification of NTRK and RET fusion-positive thyroid cancers","volume":"11","author":"Eszlinger","year":"2022","unstructured":"Eszlinger MStewardson PMcIntyre JBBox AKhalil MHyrcza MKoro KRuether DWu J & Paschke R. Systematic population-based identification of NTRK and RET fusion-positive thyroid cancers. European Thyroid Journal202211e210061. (https:\/\/doi.org\/10.1530\/ETJ-21-0061)"},{"key":"bib19","series-title":"Thyroid","first-page":"1423","article-title":"Prospective validation of ThyroSPEC molecular testing of indeterminate thyroid nodule cytology following diagnostic pathway optimization","volume":"33","author":"Stewardson","year":"2023","unstructured":"Stewardson PEszlinger MWu JKhalil MBox APerizzolo MPunjwani ZZiehr BSanyal RDemetrick DJ, et al.Prospective validation of ThyroSPEC molecular testing of indeterminate thyroid nodule cytology following diagnostic pathway optimization. Thyroid2023331423\u20131433. (https:\/\/doi.org\/10.1089\/thy.2023.0255)"},{"key":"bib20","series-title":"Endocrine Connections","first-page":"78","article-title":"NIS expression in thyroid tumors, relation with prognosis clinicopathological and molecular features","volume":"7","author":"Tavares","year":"2018","unstructured":"Tavares CCoelho MJEloy CMelo MRocha da AGPestana ABatista RFerreira LBRios ESelmi-Ruby S, et al.NIS expression in thyroid tumors, relation with prognosis clinicopathological and molecular features. Endocrine Connections2018778\u201390. (https:\/\/doi.org\/10.1530\/EC-17-0302)"},{"key":"bib21","series-title":"Journal of Nuclear Medicine","first-page":"258","article-title":"TERT promoter mutation predicts radioiodine-refractory character in distant metastatic differentiated thyroid cancer","volume":"58","author":"Yang","year":"2017","unstructured":"Yang XLi JLi XLiang ZGao WLiang JCheng S & Lin Y. TERT promoter mutation predicts radioiodine-refractory character in distant metastatic differentiated thyroid cancer. Journal of Nuclear Medicine201758258\u2013265. (https:\/\/doi.org\/10.2967\/jnumed.116.180240)"},{"key":"bib22","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"1417","article-title":"Vemurafenib redifferentiation of BRAF mutant, RAI-refractory thyroid cancers","volume":"104","author":"Dunn","year":"2019","unstructured":"Dunn LASherman EJBaxi SSTchekmedyian VGrewal RKLarson SMPentlow KSHaque STuttle RMSabra MM, et al.Vemurafenib redifferentiation of BRAF mutant, RAI-refractory thyroid cancers. Journal of Clinical Endocrinology and Metabolism20191041417\u20131428. (https:\/\/doi.org\/10.1210\/jc.2018-01478)"},{"key":"bib23","series-title":"Thyroid","first-page":"273","article-title":"Enhancing radioiodine incorporation in BRAF-mutant, radioiodine-refractory thyroid cancers with vemurafenib and the anti-ErbB3 monoclonal antibody CDX-3379: results of a pilot clinical trial","volume":"32","author":"Tchekmedyian","year":"2022","unstructured":"Tchekmedyian VDunn LSherman EBaxi SSGrewal RKLarson SMPentlow KSHaque STuttle RMSabra MM, et al.Enhancing radioiodine incorporation in BRAF-mutant, radioiodine-refractory thyroid cancers with vemurafenib and the anti-ErbB3 monoclonal antibody CDX-3379: results of a pilot clinical trial. Thyroid202232273\u2013282. (https:\/\/doi.org\/10.1089\/thy.2021.0565)"},{"key":"bib24","series-title":"Thyroid","first-page":"1634","article-title":"Mitogen-activated protein kinase pathway inhibition for redifferentiation of radioiodine refractory differentiated thyroid cancer: an evolving protocol","volume":"29","author":"Iravani","year":"2019","unstructured":"Iravani ASolomon BPattison DAJackson PRavi Kumar AKong GHofman MSAkhurst T & Hicks RJ. Mitogen-activated protein kinase pathway inhibition for redifferentiation of radioiodine refractory differentiated thyroid cancer: an evolving protocol. Thyroid2019291634\u20131645. (https:\/\/doi.org\/10.1089\/thy.2019.0143)"},{"key":"bib25","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"3698","article-title":"Targeted therapy in advanced thyroid cancer to resensitize tumors to radioactive iodine","volume":"103","author":"Jaber","year":"2018","unstructured":"Jaber TWaguespack SGCabanillas MEElbanan MVu TDadu RSherman SIAmit MSantos EBZafereo M, et al.Targeted therapy in advanced thyroid cancer to resensitize tumors to radioactive iodine. Journal of Clinical Endocrinology and Metabolism20181033698\u20133705. (https:\/\/doi.org\/10.1210\/jc.2018-00612)"},{"issue":"Supplement 1","key":"bib26","series-title":"Acta Clinica Croatica","first-page":"73","article-title":"Kinase inhibitors in the treatment of thyroid cancer: institutional experience","volume":"59","author":"Pe\u0161orda","year":"2020","unstructured":"Pe\u0161orda MKusa\u010di\u0107 Kuna SHui\u0107 DHerceg DDespot MSamard\u017ei\u0107 TGnjidi\u0107 M & Belev B. Kinase inhibitors in the treatment of thyroid cancer: institutional experience. Acta Clinica Croatica202059(Supplement 1) 73\u201380. (https:\/\/doi.org\/10.20471\/acc.2020.59.s1.09)"}],"container-title":["European Thyroid Journal"],"original-title":[],"link":[{"URL":"https:\/\/etj.bioscientifica.com\/view\/journals\/etj\/13\/3\/ETJ-23-0227.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/etj.bioscientifica.com\/downloadpdf\/journals\/etj\/13\/3\/ETJ-23-0227.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/etj.bioscientifica.com\/downloadpdf\/journals\/etj\/13\/3\/ETJ-23-0227.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:51:55Z","timestamp":1784555515000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/etj\/article\/2944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,18]]},"references-count":26,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.1530\/etj-23-0227","relation":{},"ISSN":["2235-0802"],"issn-type":[{"value":"2235-0802","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,18]]}}}